Copyright Reports & Markets. All rights reserved.

Global and China Graft Versus Host Disease (GVHD) Treatment Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Graft Versus Host Disease (GVHD) Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Monoclonal Antibodies
    • 1.2.3 MTOR Inhibitors
    • 1.2.4 Tyrosine Kinase Inhibitors
    • 1.2.5 Thalidomide
    • 1.2.6 Etanercept
  • 1.3 Market by Application
    • 1.3.1 Global Graft Versus Host Disease (GVHD) Treatment Market Share by Application: 2020 VS 2026
    • 1.3.2 Acute Graft Versus Host Disease (aGvHD)
    • 1.3.3 Chronic Graft Versus Host Disease (cGvHD)
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Graft Versus Host Disease (GVHD) Treatment Market Perspective (2015-2026)
  • 2.2 Global Graft Versus Host Disease (GVHD) Treatment Growth Trends by Regions
    • 2.2.1 Graft Versus Host Disease (GVHD) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Graft Versus Host Disease (GVHD) Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Graft Versus Host Disease (GVHD) Treatment Players by Market Size
    • 3.1.1 Global Top Graft Versus Host Disease (GVHD) Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global Graft Versus Host Disease (GVHD) Treatment Revenue Market Share by Players (2015-2020)
  • 3.2 Global Graft Versus Host Disease (GVHD) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Graft Versus Host Disease (GVHD) Treatment Revenue
  • 3.4 Global Graft Versus Host Disease (GVHD) Treatment Market Concentration Ratio
    • 3.4.1 Global Graft Versus Host Disease (GVHD) Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Graft Versus Host Disease (GVHD) Treatment Revenue in 2019
  • 3.5 Key Players Graft Versus Host Disease (GVHD) Treatment Area Served
  • 3.6 Key Players Graft Versus Host Disease (GVHD) Treatment Product Solution and Service
  • 3.7 Date of Enter into Graft Versus Host Disease (GVHD) Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Graft Versus Host Disease (GVHD) Treatment Breakdown Data by Type (2015-2026)

  • 4.1 Global Graft Versus Host Disease (GVHD) Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Type (2021-2026)

5 Graft Versus Host Disease (GVHD) Treatment Breakdown Data by Application (2015-2026)

  • 5.1 Global Graft Versus Host Disease (GVHD) Treatment Historic Market Size by Application (2015-2020)
  • 5.2 Global Graft Versus Host Disease (GVHD) Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Graft Versus Host Disease (GVHD) Treatment Market Size (2015-2026)
  • 6.2 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020)
  • 6.3 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020)
  • 6.4 North America Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Graft Versus Host Disease (GVHD) Treatment Market Size (2015-2026)
  • 7.2 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020)
  • 7.3 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020)
  • 7.4 Europe Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Graft Versus Host Disease (GVHD) Treatment Market Size (2015-2026)
  • 8.2 China Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020)
  • 8.3 China Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020)
  • 8.4 China Graft Versus Host Disease (GVHD) Treatment Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Graft Versus Host Disease (GVHD) Treatment Market Size (2015-2026)
  • 9.2 Japan Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020)
  • 9.3 Japan Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020)
  • 9.4 Japan Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Size (2015-2026)
  • 10.2 Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Graft Versus Host Disease (GVHD) Treatment Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Bristol-Myers Squibb
    • 11.1.1 Bristol-Myers Squibb Company Details
    • 11.1.2 Bristol-Myers Squibb Business Overview
    • 11.1.3 Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Introduction
    • 11.1.4 Bristol-Myers Squibb Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020))
    • 11.1.5 Bristol-Myers Squibb Recent Development
  • 11.2 Abbott
    • 11.2.1 Abbott Company Details
    • 11.2.2 Abbott Business Overview
    • 11.2.3 Abbott Graft Versus Host Disease (GVHD) Treatment Introduction
    • 11.2.4 Abbott Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 11.2.5 Abbott Recent Development
  • 11.3 AbbVie
    • 11.3.1 AbbVie Company Details
    • 11.3.2 AbbVie Business Overview
    • 11.3.3 AbbVie Graft Versus Host Disease (GVHD) Treatment Introduction
    • 11.3.4 AbbVie Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 11.3.5 AbbVie Recent Development
  • 11.4 Allergan
    • 11.4.1 Allergan Company Details
    • 11.4.2 Allergan Business Overview
    • 11.4.3 Allergan Graft Versus Host Disease (GVHD) Treatment Introduction
    • 11.4.4 Allergan Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 11.4.5 Allergan Recent Development
  • 11.5 Anterogen
    • 11.5.1 Anterogen Company Details
    • 11.5.2 Anterogen Business Overview
    • 11.5.3 Anterogen Graft Versus Host Disease (GVHD) Treatment Introduction
    • 11.5.4 Anterogen Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 11.5.5 Anterogen Recent Development
  • 11.6 Astellas Pharma
    • 11.6.1 Astellas Pharma Company Details
    • 11.6.2 Astellas Pharma Business Overview
    • 11.6.3 Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Introduction
    • 11.6.4 Astellas Pharma Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 11.6.5 Astellas Pharma Recent Development
  • 11.7 Athersys
    • 11.7.1 Athersys Company Details
    • 11.7.2 Athersys Business Overview
    • 11.7.3 Athersys Graft Versus Host Disease (GVHD) Treatment Introduction
    • 11.7.4 Athersys Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 11.7.5 Athersys Recent Development
  • 11.8 Caladrius
    • 11.8.1 Caladrius Company Details
    • 11.8.2 Caladrius Business Overview
    • 11.8.3 Caladrius Graft Versus Host Disease (GVHD) Treatment Introduction
    • 11.8.4 Caladrius Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 11.8.5 Caladrius Recent Development
  • 11.9 Eli Lilly
    • 11.9.1 Eli Lilly Company Details
    • 11.9.2 Eli Lilly Business Overview
    • 11.9.3 Eli Lilly Graft Versus Host Disease (GVHD) Treatment Introduction
    • 11.9.4 Eli Lilly Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 11.9.5 Eli Lilly Recent Development
  • 11.10 GlaxoSmithKline
    • 11.10.1 GlaxoSmithKline Company Details
    • 11.10.2 GlaxoSmithKline Business Overview
    • 11.10.3 GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Introduction
    • 11.10.4 GlaxoSmithKline Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 11.10.5 GlaxoSmithKline Recent Development
  • 11.11 Glenmark
    • 10.11.1 Glenmark Company Details
    • 10.11.2 Glenmark Business Overview
    • 10.11.3 Glenmark Graft Versus Host Disease (GVHD) Treatment Introduction
    • 10.11.4 Glenmark Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 10.11.5 Glenmark Recent Development
  • 11.12 Kadmon Holdings
    • 10.12.1 Kadmon Holdings Company Details
    • 10.12.2 Kadmon Holdings Business Overview
    • 10.12.3 Kadmon Holdings Graft Versus Host Disease (GVHD) Treatment Introduction
    • 10.12.4 Kadmon Holdings Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 10.12.5 Kadmon Holdings Recent Development
  • 11.13 Osiris Therapeutics
    • 10.13.1 Osiris Therapeutics Company Details
    • 10.13.2 Osiris Therapeutics Business Overview
    • 10.13.3 Osiris Therapeutics Graft Versus Host Disease (GVHD) Treatment Introduction
    • 10.13.4 Osiris Therapeutics Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 10.13.5 Osiris Therapeutics Recent Development
  • 11.14 Sanofi
    • 10.14.1 Sanofi Company Details
    • 10.14.2 Sanofi Business Overview
    • 10.14.3 Sanofi Graft Versus Host Disease (GVHD) Treatment Introduction
    • 10.14.4 Sanofi Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 10.14.5 Sanofi Recent Development
  • 11.15 Takeda
    • 10.15.1 Takeda Company Details
    • 10.15.2 Takeda Business Overview
    • 10.15.3 Takeda Graft Versus Host Disease (GVHD) Treatment Introduction
    • 10.15.4 Takeda Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2015-2020)
    • 10.15.5 Takeda Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Graft Versus Host Disease (GVHD) Treatment Scope and Market Size
    Graft Versus Host Disease (GVHD) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Graft Versus Host Disease (GVHD) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Monoclonal Antibodies
    MTOR Inhibitors
    Tyrosine Kinase Inhibitors
    Thalidomide
    Etanercept

    Market segment by Application, split into
    Acute Graft Versus Host Disease (aGvHD)
    Chronic Graft Versus Host Disease (cGvHD)

    Based on regional and country-level analysis, the Graft Versus Host Disease (GVHD) Treatment market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Graft Versus Host Disease (GVHD) Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Bristol-Myers Squibb
    Abbott
    AbbVie
    Allergan
    Anterogen
    Astellas Pharma
    Athersys
    Caladrius
    Eli Lilly
    GlaxoSmithKline
    Glenmark
    Kadmon Holdings
    Osiris Therapeutics
    Sanofi
    Takeda

    Buy now